Product Details
| Cat.No. | EDC08107 | Product Name | SARM1 Knockout HEK293 Cell Line |
|---|---|---|---|
| Cell Line | HEK293 | Cellosaurus ID | CVCL_0045 |
| Cell Line Synonyms | Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293 | Gene | |
| NCBI Gene ID | Gene Synonyms | HsTIR|MyD88-5|SAMD2|SARM|hSARM1 | |
| Summary |
Enables NAD+ nucleosidase activity; NAD+ nucleosidase activity, cyclic ADP-ribose generating; and identical protein binding activity. Involved in NAD catabolic process and response to axon injury. Is active in mitochondrion. [provided by Alliance of Genome Resources, Apr 2025]
|
Associated Diseases | Non-tumor |
| Morphology | Adherent | Passage Ratio | 1/5,2days |
| Complete Culture Medium | DMEM + 10% FBS | Freezing Medium | 95% Complete culture medium+ 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
STR Profile
| Loci | STR Info (Sample Cell) Sample Cell Line: HEK293 | STR Info (Cell bank) Cell Line: HEK293 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | X | ||
| CSF1P0 | 12 | 11 | 12 | |
| D2S1338 | 19 | 19 | ||
| D3S1358 | 15 | 17 | 15 | 17 |
| D5S818 | 8 | 8 | 9 | |
| D7S820 | 11 | 12 | 11 | 12 |
| D8S1179 | 12 | 14 | 12 | 14 |
| D13S317 | 12 | 14 | 12 | 14 |
| D16S539 | 9 | 13 | 9 | 13 |
| D18S51 | 17 | 18 | 17 | 18 |
| D19S433 | 15 | 18 | 15 | 18 |
| D21S11 | 28 | 30.2 | 28 | 30.2 |
| FGA | 23 | 23 | ||
| Penta D | 9 | 10 | 9 | 10 |
| Penta E | 7 | 15 | 7 | 15 |
| TH01 | 7 | 9.3 | 7 | 9.3 |
| TPOX | 11 | 11 | ||
| vWA | 16 | 19 | 16 | 19 |
| D6S1043 | 11 | 11 | ||
| D12S391 | 19 | 21 | 11 | 15 |
| D2S441 | 11 | 15 | 11 | 15 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying SARM1 function, SARM1 Knockout HEK293 Cell Line or SARM1 overexpression HEK293 Cell Line?
The choice depends on whether you are studying SARM1's role as the central executioner of axon degeneration or its enzymatic activity as a NAD⁺ glycohydrolase. The Knockout line is the standard tool for asking whether SARM1 is required for activation-induced NAD⁺ depletion — SARM1 is a dormant NAD⁺ hydrolase that, upon activation by NMN/NAD⁺ ratio increase or injury, catalyzes catastrophic NAD⁺ destruction triggering Wallerian axon degeneration. Overexpression is useful for studying constitutively active SARM1 mutants (E642A) or testing inhibitor specificity.
For SARM1 research, the EDITGENE Knockout in HEK293 is the standard mechanistic platform — HEK293 has been extensively used for SARM1 biochemistry, structure-function studies, and inhibitor screening. Rescue with wild-type, catalytically-dead (E642A or constitutively active depending on the mutation), or autoinhibition-released SARM1 enables comprehensive mechanism studies. SARM1 is a major therapeutic target for chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and other axonopathies — multiple SARM1 inhibitors are in clinical development.
Is this SARM1 Knockout HEK293 Cell Line compatible with overexpression rescue experiments?
Yes. SARM1 rescue experiments are well-established for axon degeneration research:
• Construct design: use a codon-modified SARM1 sequence with a small C-terminal tag (FLAG, HA). SARM1 contains an N-terminal mitochondrial targeting sequence/ARM autoinhibitory domain, central SAM dimerization domain, and C-terminal TIR catalytic domain — all essential for regulated activation.
• Catalytically-dead rescue: the E642A mutation in the TIR domain abolishes NAD⁺ hydrolase activity and is the standard specificity control.
• Constitutively active rescue: ARM domain mutations or deletions release autoinhibition, generating constitutively active SARM1 useful for gain-of-function studies.
• Functional readout: rescue should restore activation-induced NAD⁺ depletion measured by NAD⁺/NADH ratio assays following NMN treatment or other activation triggers.
HEK293 transduces efficiently with lentivirus and is the standard heterologous expression background for SARM1 biochemistry.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.